Cited by 25Genomics and Rare DiseasesGenetics and Neurodevelopmental DisordersAutism Spectrum Disorder Research

Molecular subtyping and improved treatment of neurodevelopmental disease

Open access
Stessman, Holly A. F., Turner, Tychele N., Eichler, Evan E.·2016·Genome Medicine

Abstract

The next-generation sequencing revolution has substantially increased our understanding of the mutated genes that underlie complex neurodevelopmental disease. Exome sequencing has enabled us to estimate the number of genes involved in the etiology of neurodevelopmental disease, whereas targeted sequencing approaches have provided the means for quick and cost-effective sequencing of thousands of patient samples to assess the significance of individual genes. By leveraging such technologies and clinical exome sequencing, a genotype-first approach has emerged in which patients with a common genotype are first identified and then clinically reassessed as a group. This approach has proven a powerful methodology for refining disease subtypes. We propose that the molecular characterization of these genetic subtypes has important implications for diagnostics and also for future drug development. Classifying patients into subgroups with a common genetic etiology and applying treatments tailored to the specific molecular defect they carry is likely to improve management of neurodevelopmental disease in the future.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13073-016-0278-z

Cites

105 of 105 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Pathogenic variants in the same genes are identified in individuals with a variety of different clinically defined brain disorders, including ASD, ID, epilepsy, schizophrenia, and other neurodevelopmental and neuropsychiatric conditions.

    “It has also become clear that pathogenic variants in the same genes are identified in individuals with a variety of different clinically defined brain disorders, including ASD, intellectual disability (ID), epilepsy, schizophrenia, and other neurodevelopmental and neuropsychiatric conditions.”

    From Insufficient Evidence for “Autism-Specific” Genes (2020) · cites this paper as [5]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [37]Consortium EA. ExAC Browser. Cambridge, MA. 2015. http://exac.broadinstitute.org/. Accessed 8 September 2015.

Cited by

Sorted by citations

Authors
Stessman, H. A. F., Turner, T. N., & Eichler, E. E.
Affiliations
  • University of Washington (US)
  • Howard Hughes Medical Institute (US)
Corresponding author
Eichler, Evan E.
Venue
Genome Medicine
Published
2016-02-25
Volume
8
Issue
1
Pages
22-22
ISSN
1756-994X (ISSN-L)
OpenAlex
W2277635465
Cited by
25
References
105
Citations by year
2026: 1 · 2023: 3 · 2022: 1 · 2021: 1 · 2020: 7 · 2018: 3 · 2017: 6 · 2016: 3
FWCI
3.23
Type
journal article
Language
en
Open access
Locations
  • Genome Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Simons Foundation (336475)
  • National Institute of Mental Health (R01MH101221)
  • National Human Genome Research Institute (T32HG00035)
  • Howard Hughes Medical Institute (NA)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
Keywords
neurodevelopmental disorders, molecular subtyping, genotype-first approach, targeted sequencing, exome sequencing, genetic diagnosis, precision medicine, drug development, disease classification
MeSH terms
Genotype, Humans, Genome, Human, Sequence Analysis, DNA, Genetic Predisposition to Disease, Molecular Diagnostic Techniques, High-Throughput Nucleotide Sequencing, Neurodevelopmental Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review